Assajos bioanalítics quimioluminescents per biomarcadors clínics by Campmajó Galván, Guillem
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Tutor/s 
Dra. Maria Sarret Pons  
Departament de Ciència dels Materials i 
Química Física 
Dr. Aldo Roda 
Università di Bologna 
 
Treball Final de Grau 
Chemiluminescent bioanalytical assays for clinical biomarkers. 
Assajos bioanalítics quimioluminescents per biomarcadors 
clínics. 
Guillem Campmajó Galván 
June 2017 
 
  
 
 Aquesta obra esta subjecta a la llicència de: 
Reconeixement–NoComercial-SenseObraDerivada 
 
http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 
  
 
 
 
 
 
 
 
 
 
El meu agraïment al Prof. Aldo Roda i a la Prof. Mara Mirasoli per brindar-me l’oportunitat 
de realitzar aquest treball al grup d’investigació de Química Analítica i Bioanalítica de 
l’Università di Bologna i per l’ajut en la realització d’aquest estudi. També, la meva gratitud a la 
Dra. Martina Zangheri i al Dr. Donato Calabria pel seu recolzament diari, el seu consell i la seva 
dedicació. 
També, donar les gràcies a la Dra. Maria Sarret pel seu suport i la seva guia malgrat la 
distància. 
Finalment, agraeixo a tots els integrants del laboratori haver-me fet sentir com a casa i fer 
d’aquesta, una experiència que difícilment oblidaré.      
 
 
 
  
 
REPORT 
Chemiluminescent bioanalytical assays for clinical biomarkers.  1 
 
 
CONTENTS 
1. SUMMARY 3 
2. RESUM 5 
3. INTRODUCTION 7 
3.1. Point-of-care testing devices 7 
3.2. Luminescence and chemiluminescence 7 
3.2.1. Luminescence’s processes. Chemiluminescence 7 
3.2.2. Chemiluminescent quantum yield 9 
3.2.3. Chemiluminescent detection 9 
3.2.4. Light detection technologies for biosensing 11 
3.3. Biospecific molecular recognition 12 
3.3.1. Immunological methods 13 
3.3.2. Enzymatic methods 14 
3.4. Microfluidic systems 14 
3.4.1. Microfluidic chip devices 14 
3.4.2. Paper-based analytical devices 15 
3.5. Development of portable analytical devices 16 
3.5.1. Life-Marker detection in extraterrestrial environment 16 
3.5.2. Point-of-care testing for measurement of glycemia 17 
4. OBJECTIVES  19 
5. EXPERIMENTAL SECTION 20 
5.1. Development of chemiluminescent immunoassay for detection of ATP 20 
5.1.1. Reagents 20 
5.1.2. Instruments 21 
5.1.3. Selection of the reagents and optimization of the experimental conditions: 
nitrocellulose-based chemiluminescent immunoassay 21 
2 Campmajó Galván, Guillem 
 
 
5.1.4. Experimental procedure of CL-based indirect competitive immunoassay in 
microplate format 25 
5.1.5. Data elaboration 26 
5.2. Paper-based device with chemiluminescent detection using CMOS for the 
determination of glucose 26 
5.2.1. Reagents 26 
5.2.2. Instruments 26 
5.2.3. From CCD to CMOS 27 
5.2.4. Origami device 28 
5.2.5. Adapters for origami-detection 30 
5.2.6. Experimental procedure 31 
5.2.7. Data elaboration 32 
6. DEVELOPMENT OF CHEMILUMINESCENT IMMUNOASSAY FOR DETECTION OF ATP: 
DISCUSSION 33 
6.1. Optimization of the method on nitrocellulose platform 33 
6.1.1. Indirect competitive immunoassay (a) 33 
6.1.2. Indirect competitive immunoassay (b) 34 
6.1.3. Direct competitive immunoassay  35 
6.2. Optimization of chemiluminescent immunoassay on microplate format 36 
6.2.1. Immobilization of ATP-OVA 36 
6.2.2. Incubation time 37 
6.2.3. Dilution of Anti-ATP antibody 38 
6.3. Calibration curve 39 
7. PAPER-BASED DEVICE WITH CHEMILUMINESCENT DETECTION USING CMOS FOR THE 
DETERMINATION OF GLUCOSE: DISCUSSION 41 
7.1. CMOS sensor detectability and resolution 41 
7.2. Calibration curve 42 
7.3. Application on real samples: calibration curve in human serum 43 
8. CONCLUSIONS  45 
9. REFERENCES AND NOTES  47 
10. ACRONYMS  49 
 
Chemiluminescent bioanalytical assays for clinical biomarkers.  3 
 
 
1. SUMMARY 
A growing field of research in chemical-biological analysis, aimed at improving and 
simplifying analytical procedures, is the development of Lab-On-Chip devices. Allowing the 
direct analysis at the point of need, the use of such portable miniaturized systems offers many 
applications ranging from environmental analysis to complementary diagnostics for personalized 
medicine. Moreover, due to its numerous advantages over traditional photon emission detection 
techniques, chemiluminescence has proven to be suitable for that type of devices.  
This study has been focused on the development of two chemiluminescent bioanalytical 
assays for clinical biomarkers. In particular, the optimization of bioanalytical assays required the 
study of different materials and procedures for obtaining optimal performances, with special 
attention to the development of suitable immobilization procedures and to the selection of 
proper reagents, materials and chemiluminescent detectors.  
On one hand, a chemiluminescent immunoassay for detection of ATP has been optimized. 
Among three different immunoassay formats, the indirect competitive immunoassay based on 
the immobilization of ATP conjugated to ovalbumin was selected as the most appropriate. After 
its optimization in 96-microwells platform, a calibration curve was obtained. 
On the other hand, a “paper-based” analytical device, which exploits an enzymatic reaction 
for quantification of glucose in serum sample, has been adapted from a CCD camera to a more 
compact and portable CMOS sensor for the detection. In result, the adaptation was successfully 
achieved without a significant loss in detectability.   
Keywords: Chemiluminescence, Lab-On-Chip, bioassays, immunoassay, enzymatic assay, 
paper-based device, CMOS sensor, ATP, glucose, biomarker. 
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2. RESUM 
Un camp d’investigació en creixement en anàlisi química-biològica, dirigit a millorar i 
simplificar els procediments analítics, és el desenvolupament dels dispositius “Lab-On-Chip”. 
Permetent l’anàlisi directa en el punt de necessitat, l’ús d’aquests sistemes portàtils 
miniaturitzats ofereix un ampli rang d’aplicacions que van des d’anàlisis mediambientals fins al 
diagnòstic complementari per la medicina personalitzada. A més, degut a les seves nombroses 
avantatges respecte les tècniques clàssiques de detecció d’emissió de fotons, la 
quimioluminescència ha demostrat ser una tècnica convenient per a aquest tipus de dispositius.  
Aquest estudi s’ha basat en el desenvolupament de dos assajos bioanalítics 
quimioluminescents per biomarcadors clínics. En particular, l’optimització dels assajos 
bioanalítics ha requerit l’estudi de diferents materials i procediments per a l’obtenció de 
resultats òptims, amb especial atenció en el desenvolupament dels procediments 
d’immobilització adequats i en la selecció apropiada dels reactius, materials i de la detecció 
quimioluminescent.   
Per una banda, un immunoassaig quimioluminescent per a la detecció d’ATP ha estat 
optimitzat. D’entre tres formats d’immunoassaig, un immunoassaig competitiu indirecte basat en 
la immobilització d’ATP conjugat a ovoalbúmina va ser triat com el més adequat. Després de la 
seva optimització en microplaca com a plataforma, es va obtenir una corba de calibratge.  
D’altra banda, un dispositiu analític basat en paper, que empra una reacció enzimàtica per 
a la quantificació de glucosa en una mostra de sèrum, s'ha adaptat d'una càmera CCD 
ultrasensible a un sensor CMOS, més compacte i portàtil, com a detector. A partir dels resultats 
obtinguts, es va demostrar que l'adaptació es va aconseguir de forma exitosa sense una 
pèrdua significativa en la detectabilitat. 
Paraules clau: Quimioluminescència, “Lab-On-Chip”, bioassajos, immunoassaig, assaig 
enzimàtic, dispositiu basat en paper, sensor CMOS, ATP, glucosa, biomarcador. 
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3. INTRODUCTION 
3.1. POINT-OF-CARE TESTING DEVICES 
In the last years, one of the main issues in the field of Analytical Chemistry has been the 
development of analytical systems capable of providing fast and reliable analytical results 
exploiting easy-to-use and portable devices suitable for performing the analysis directly at the 
point of need. In diagnostic field this approach is known as “Point-of-care testing” (POCT) and it 
must meet the following basic requirements [1]: 
 The sample has to require a minimum or nil pre-treatment before the analysis.  
 Structural characteristics as small size, reduced weigh and the presence of an 
autonomous electrical power should ensure the portability of the device.  
 People without knowledge in the field are supposed to use the system, so it has to 
be user-friendly. 
 Qualitative or quantitative results, depending on the objective of the analysis, must 
be obtained by treating the primary measurement output provided by the detection 
system. 
In addition, POCT devices should be based on low cost and disposable components and it 
should guarantee stability and durability from the fabrication to their use. Other important 
characteristics of POCT systems are the possibility to automate the analytical process, to have 
an internal control for the auto-calibration, to provide a wide measurement range or the ability to 
determinate multiple analytes simultaneously. 
3.2. LUMINESCENCE AND CHEMILUMINESCENCE 
3.2.1. Luminescence’s processes. Chemiluminescence 
Luminescence consists in the emission of electromagnetic radiation in the UV-Vis region 
(200-800 nm), due to molecules or atoms, as a result of a transition from an excited electronic 
state to a state with a lower energy, normally the ground state.  
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Different forms of luminescence are classified depending on the origin of the photon’s 
production. Thus, for example, a physic stimulus as electromagnetic radiation can produce 
fluorescence or phosphorescence, while, chemical luminescence is caused by a chemical 
reaction. 
According to the stimulus able to trigger the reaction, chemical luminescence can be 
classified in different subtypes: chemiluminescence (CL) and bioluminescence are referred to 
the chemical production of light started by mixing the reagents and, in case of BL, using 
enzymes and photoproteins isolated from living organisms [2]; in electrogenerated 
chemiluminescence, reagents are produced during an electrochemical reaction that occurs at 
the surface of an electrode and the light is generated by the relaxation of that molecules [3]; in 
thermochemiluminescence the light is produced by the thermal-induced decomposition of a 
molecule [4].     
A chemical reaction produces light when it fulfils some specific requirements [5]: 
 The reaction needs to be exergonic enough to populate an electronically excited 
singlet state. The emission of photons in the region between 400 and 750 nm 
requires an energy of 40-70 kcal·mol-1 
 The excited state’s formation has to be accessible respect the ground state on 
the reaction coordinate.  
 To carry out the photon emission, the release of energy has to be feasible. In 
direct CL, the excited molecule responsible of the light is produced by the 
chemical reaction, whereas, in indirect CL, the reaction produces an excited 
compound, which cannot release light, but transfers that energy to a molecule 
that can, as shown in Figure 3.1.  
 
 
 
 
 
 
Figure 3.1 Direct (a) and indirect (b) CL reaction. 
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3.2.2. Chemiluminescent quantum yield 
     The capacity of the CL system to emit light is expressed by the CL quantum yield (ΦCL), 
defined as the number of photons emitted per reacting molecule and represented by the 
expression:  
ΦCL = ΦR ΦES ΦF 
where ΦR is the chemical yield of the reaction, ΦES is the fraction of molecules that arrived at the 
excited state and ΦF is the fraction of molecules that returns to the ground state by releasing 
photons. In indirect CL reactions, ΦET, which is the process of energy transfer, should be added. 
Normally, a CL reaction has a value of the CL quantum yield between 0’001 and 0’1. There are 
different factors that influence that value: the intrinsic luminescent power of the excited 
molecule, the pH, the temperature or the concentration of the reagents.  
3.2.3. Chemiluminescent detection 
CL analytical techniques have achieved great popularity in the recent years thanks to their 
ability to produce photons with no need for photoexcitation, as it occurs in fluorescence 
detection, thereby avoiding problems arising from light scattering, background fluorescence or 
light source instability. CL detection techniques are characterised by a high signal-to-noise ratio, 
hence a high sensitivity, as the light signal is generated by the chemical reaction in the dark. 
CL-based detection is particularly suited for miniaturized analytical devices, as it avoids the 
need for external radiation sources and complex optical systems combining ﬁlters and lenses 
[6]. Moreover, CL detection shows wide dynamic ranges, thus facilitating analysis of samples 
with very different analyte concentrations.  
In contrast to other spectroscopic techniques, the CL signal is not constant. However, it 
presents a kinetic that depends on the reaction rate, which decreases over time. Figure 3.2 
shows two kind of signals that can be produced by a CL reaction: flash or glow kinetic.  
 CL reactions that have a flash kinetic, reach instantly the maximum intensity and 
the signal decreases exponentially over time. That kinetic is very fast, so it 
requires an instrumentation able to activate the reaction inside the device 
ensuring the detection of the signal. Moreover, as the highest intensity of the 
signal is influenced by different factors (e.g. temperature, pH and presence of 
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interferents), it is not a reliable data. So, in this case the signal is integrated over a 
certain time.  
 CL reactions that have a glow kinetic are normally catalysed by enzymes. In that 
case, the emission achieve quickly a constant intensity and is maintained over a 
relatively long time. When the substrate is in excess, the maximum signal intensity 
is proportional to the activity of the enzyme which is related to analyte’s 
concentration.  
 
 
 
 
 
 
 
 
 
 
The oxidation of luminol (5-Amino-2,3-dihydrophthalazine-1,4-dione), shown in Figure 3.3, 
under alkaline conditions in presence of an oxidant agent, as hydrogen peroxide, is one of the 
most employed CL reactions. Due to the basic pH used, luminol is found as a dianion, which 
presents keto-imine tautomerization. The disproportionation of hydrogen peroxide produces 
water and oxygen. That last one, reacts with the imine form of the luminol’s dianion producing 
the excited 3-aminophtalate that when it decays to the ground state, a photon is released 
emitting at 428 nm (blue light emission). 
That reaction can be catalysed by different molecules, from enzymes to metallic 
coordination complexes. Thus, for example, horseradish peroxidase (HRP) is a type of 
peroxidase enzyme commonly used as a label in binding assays thanks to its signal 
amplification capability [7]. Another example is the hexacyanoferrate (III) ion. In that case, a 
redox reaction is produced between the catalyst, which is reduced, and the hydrogen peroxide 
Figure 3.2 Flash (a) and glow (b) CL reaction kinetics. 
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(also luminol can be oxidised due to hexacyanoferrate (III) reduction, but this reaction is rather 
slower).   
Luminol’s oxidation allows the determination of the activity of the enzyme used, but also, it is 
possible to determinate species involved in a reaction able to be coupled to the luminescent 
one. For example, reactions which produce hydrogen peroxide can be coupled to the CL system 
(e.g. reactions catalysed by oxidase enzymes).  
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4. Light detection technologies for biosensing 
The main requisite of chemical luminescence measurements is the ability to collect as much 
light as possible to achieve the highest detectability. In contrast to photoluminescence, where 
the optics geometry is crucial to minimizing the excited light interference, a much-simplified 
optics can be used. Several technological solutions have been proposed for ultrasensitive 
chemical luminescence detection in biosensors and bioassays. 
- Photomultiplier tubes:  
The reference detection system for chemical luminescence is the photomultiplier tube 
(PMT), which provides the highest sensitivity. Typical PMT devices present a high quantum 
Figure 3.3 Oxidation reaction of luminol by hydrogen peroxide under alkaline conditions and in 
presence of a catalyst 
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efficiency in the spectral range between 360-670 nm, covering the emission wavelengths of the 
majority of CL probes. Implementation of conventional PMT-based devices in biosensors has 
been hampered by their high cost, large size, and requirement for a power source.  
- Charge-transfer detectors:  
The requirement for portable light detectors with high sensitivity has led to the use of 
alternative light sensors, such as charge-coupled devices (CCD), complementary metal oxide 
semiconductors (CMOS), and silicon and organic photodiodes. Portable charge-transfer 
detectors (CCD and CMOS) have become widespread thanks to their compact size and their 
ability to image and quantify multiple spots simultaneously on the detection area of the sensor 
[8, 9, 10]. 
The renewed interest in CMOS derives from their small size, low power consumption, 
camera-on-a-chip integration, and lower fabrication costs [11, 12]. In first generation CMOS, the 
majority of the pixel area was dedicated to the support transistors, with a limited photon-sensing 
area (fill factor). Modern back-illuminated CMOS, in which the entire area of each pixel is used 
for photon capture, offer higher sensitivity, ensuring high signal-to-noise ratio even in low-light 
conditions. The pixel size is reduced, increasing image resolution and device compactness. 
Imaging with charge-transfer sensors requires simple optics to obtain reasonable resolution and 
to prevent light cross-talk between adjacent objects. Alternatively, optics-free “contact imaging” 
configurations can be used, in which the surface where the bioassays take place is in contact 
with the sensor [13].  
- Thin-film photosensors:  
The integration of relatively inexpensive thin-film photosensors directly in the analytical chip 
is another notable technological advance, which could reduce costs, electrical power 
consumption, and memory storage space. By optimizing chip design, sensor architecture, and 
readout electronics to maximize photon collection efficiency, analytical performances 
comparable with CCD have been achieved in a portable integrated device [14].  
3.3. BIOSPECIFIC MOLECULAR RECOGNITION 
The specific interaction between two or more molecules that exhibit molecular 
complementarity caused by noncovalent bonding is known as molecular recognition [15]. That 
noncovalent bonding can be: hydrogen bonding, hydrophobic forces, Van der Waals forces, π- 
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π interactions, halogen bonding and electrostatic and/or electromagnetic effects. Molecular 
recognition reactions are widely used in analytical chemistry’s field as they are a sensitive and 
specific biosensing tool.  
In spite of the variety of molecular recognition reactions, this work will only focus on 
immunological and enzymatic methods.  
3.3.1. Immunological methods 
Immunoassays (IA) are well established bioanalytical methods widely employed for 
screening procedures offering high sample throughput, high sensitivity and reduced 
requirements for sample pre-analytical preparation, owing to the high specificity of antigen-
antibody binding reaction. Appropriate antibodies bind with high selectivity to their antigen and it 
is possible to design IA for a wide range of analytes. The antibody is a protein that is able to 
recognize and bind selectively its own specific antigen by an affinity reaction. The chemical 
structure of the antigen allows its binding to the paratope of the antibody with high affinity, 
establishing an equilibrium reaction. This reaction depends on the concentration of the analytes 
if the antibody and the other reagents are present in constant concentrations. There are a great 
variety of antibodies that can be raised up for different kind of analytes such as small organic 
molecules (i.e. pesticides, hormones, pharmaceuticals or toxic small molecules), biopolymers 
(i.e. peptides, proteins, DNA) or the outer membrane of cells or organelles (i.e. viruses, bacteria, 
spores, fungi, protozoa, eukaryotic cells), thus allowing the development of rapid and sensitive 
IA for biological, environmental or food analysis. Monoclonal and polyclonal antibodies are 
available for IA [16].  
The detection of the formed immune-complex is commonly performed through the use of 
labelled reagents. Enzymes can be chemically coupled to primary detection antibodies, to 
antigens, to a secondary antibody (which binds to the unlabelled primary antibody), or to 
streptavidin (which binds to biotinylated antibodies) to obtain enzymatic tracers. 
IA can be classified into competitive and non-competitive formats. While in the competitive 
format an analyte derivative is added and competes with the analyte present in the sample for 
binding to the antibody, the non-competitive IAs (also known as “sandwich IA”) are based on the 
directly detection of the immune-complex. The selection of the format depends on the analyte 
size: competitive IA being applied for the detection of small analytes containing one binding site 
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for antibody recognition, while sandwich IA are applied to high molecular weight molecules that 
consist of two or more binding sites [17].  
Since the labelling process reduces the activity of antibodies, high amounts of antibodies 
are needed, which is expensive, especially for sensitive detection antibodies. So, as an 
alternative, it can be useful to label secondary antibodies (anti-human, anti-rabbit, anti-mouse, 
etc.) that react with unlabelled primary antibodies (human, rabbit, mouse, etc.) at the solid 
support. 
The most commonly IA format for laboratory routine analysis is the microtiter plate-based IA. 
This format uses a solid support for the antibody–antigen reaction and it requires the separation 
of the antibody-antigen complex from free antibodies.  
3.3.2. Enzymatic methods 
Enzymes are molecules, usually proteins that act as catalysts for a large number of 
biological processes. An enzymatic reaction begins with the formation of the enzyme-substrate 
complex, caused by the bounding of the substrate with the active site of the enzyme. Then the 
complex can return to its initial form or the product can be obtained.  
E + S ⇆ ES ⇆ E + P 
They have an important role in clinical analysis either as analytes or as reagents for their 
substrate determination. In this last case, they allow the direct analysis of biological samples 
without pretreatment, due to the specificity of enzymes for their substrates.  
3.4. MICROFLUIDIC SYSTEMS  
Lab-On-Chip (LOC) devices, which are a type of POCT systems based on microfluidics, 
have gained much attention due to their favourable characteristics in terms of reduced size and 
weight, very low sample and reagent consumption, reduced analysis time and, often, superior 
achievable performances in terms of limits of detection.  
3.4.1. Microfluidic chip devices 
Microfluidic technologies have a great potential for developing portable analytical devices 
due to the advantages in size, volume requirements and time for the analysis [18, 19, 20, 21, 
22]. Traditional multiwell plates format commonly used in laboratory analysis are based on the 
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binding between the analytes in sample solution and the capture molecules immobilized on solid 
surfaces, while the analytes not bound to the capture molecules are removed during washing 
steps. These methods usually need relatively long incubation times and several hours are 
required to complete an analysis (from 1 to 24 h). Microfluidic immunosensors are able to 
overcome this limitation, since the increased surface-to-volume ratio makes it possible to have a 
more efficient transport in the immunoreactions, leading to a faster analysis. Indeed under flow 
in microchannels, this transport process is thought to be kinetically rapid due to the proximity of 
the analytes to the surface, [23] and the rapid replenishment of depleted analytes in the 
boundary layer by convective flow [24]. Moreover a miniaturized microchannel dimension 
provides the reduction of consumption of samples and reagents and automated integration with 
other functions, such as valves, pumps, mixers, and detectors allow achieving a POC goal [25]. 
For these reasons microfluidic systems have recently attracted great deal of attention as 
immunosensor platforms [26]. Microfluidic chips allow to develop arrays of specific capture 
probes on a functionalized surface, without impairing their binding ability. This system makes it 
also possible to perform multiplex analyses by spatially separating several reaction area, each 
of one specific for a different analyte that is recognized by its specific position. 
Different methods can be employed to move liquids in microfluidics, such as pressure-driven 
flow, electro-osmosis, or acceleration. One of the simplest approaches for producing flow in 
microchannels is to use capillary forces [27]. Capillary-driven flow requires no peripheral 
equipment, and this concept is used for portable immunodiagnostic tests [28]. 
3.4.2. Paper-based analytical devices 
An emerging microfluidic platform based on capillary forces, are those based on porous 
materials. Hydrophobic barriers patterned into a porous, hydrophilic material provide channels 
for the controlled and autonomous wicking of fluids to testing zones within a device. These 
materials operate independently of equipment and therefore make excellent substrates for the 
development of POCT diagnostic devices. Among porous materials, paper is an attractive 
substrate which allows producing diagnostic devices employing minimal infrastructure (e.g., a 
wax printer to pattern microfluidic channels and a pipette to dispense reagents) and inexpensive 
raw materials. In addition devices can be prototyped rapidly (ca. minutes from design to 
production) [29].  
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3.5. DEVELOPMENT OF PORTABLE ANALYTICAL DEVICES 
 3.5.1. Life-Marker detection in extraterrestrial environment 
The search for life outside the Earth is one of the main goals of the scientific community. 
Nowadays, this research is focused on Mars as it presents some indications of possible past or 
present life: landforms produced by flowing water in the past [30] or the presence of methane in 
the Martian atmosphere [31] are some examples.  
Current research strategies to find evidence of life in extra-terrestrial environment are based 
on the in-situ detection of organic molecules: amino acids, polycyclic aromatic hydrocarbons, 
nucleic acids, polysaccharides and other molecular systems characteristic of organized 
biological systems. Recently Life Marker Chip (LMC) [32] has been proposed to detect organics 
in the form of biomarkers that might be associated with extinct life, extant life or abiotic sources 
of organics.  
LOC devices are extremely suitable for space missions and are under investigation in view 
of future planetary exploration. On this trail, the project Planetary Life Explorer with Integrated 
Analytical Detection and Embedded Sensors (PLEIADES), carried out at the Laboratory of 
Analytical and Bioanalytical Chemistry (headed by Prof. Aldo Roda) of the University of Bologna 
in collaboration with Sapienza University of Rome, aims to design and develop a portable 
biosensor for detecting life biomarkers. 
An important step for the development of this system is the selection of a biomarker suitable 
for highlighting the presence of extinct or extant life. Although many chemistries could support 
life, the study of life in Mars is based on our knowledge of terrestrial life since, as on Earth, life is 
directly related with water. Adenosine triphosphate (ATP), was chosen as life biomarker.  This 
molecule is composed by the nucleobase adenine, ribose and three phosphate groups and, 
according to a selection of molecular targets made for a European Space Agency’s mission 
[33], it is classified as an extant biomarker. It is known for being an energy source and 
extracellular signalling mediator, thus, finding ATP on Mars would suggest the possibility of the 
presence of biological life.  
In particular, PLEIADES project focuses on the development of a competitive IA based on 
CL detection for the identification of ATP. The IA will be implemented into a portable device 
(Figure 3.4) that is being developed exploiting a microfluidic network based on capillary forces 
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for the handling of samples and reagents, integrated with an array of thin film hydrogenated 
amorphous silicon (a-Si:H) photosensors for the detection of the analytical CL signal. The 
implementation of the CL bioassay into the compact and fully-integrated device will provide a 
new analytical platform for the multiparametric detection of bio-organic molecules outside of the 
Earth. 
 
 
 
 
 
 
 
 
 
3.5.2. Point-of-care testing for measurement of glycemia 
Glucose is a chiral aldose monosaccharide that has two enantiomers: D-glucose, which is 
by far the most widespread in nature, and L-glucose. Due to its 6 carbon atoms, it is classified 
as a hexose and in aqueous solution it generally exists as a pyranose, which is its cyclic form 
resulting from the nucleophilic addition reaction between the aldehyde group at C-1 and the 
hydroxyl group at C-5. This cyclization provides a new stereogenic centre creating two 
diastereoisomers: α and β.  
In the human body, there is an intrinsic system that monitors the concentration of glucose in 
blood. In a healthy body, glycemia is in the range of 70 and 110 mg/dL (3,9 and 6,1 mM). Higher 
(hyperglycemia) or lower (hypoglycemia) values may derive from different pathologies. Diabetes 
is a common example of hyperglycemia.  
There are several LOC enzymatic devices that make life easier for diabetes patients. They 
are all based on the glucose oxidation to gluconolactone, described in Figure 3.5, catalysed by 
the glucose oxidase (GOx) enzyme. GOx is a dimeric protein that acts specifically on β-D-
glucose (not on α-D-glucose). 
Figure 3.4 Design of the microfluidic portable device expected to be 
developed in the PLEIADES project.  
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In the first devices, the oxygen of the solution consumed during the reaction was determined 
amperometrically. However, to avoid the intrinsic limit due to the dependence of the signal on 
the initial oxygen concentration, amperometric biosensors of second generation had been 
developed. In that case, after the glucose oxidation, the enzyme is oxidized by a redox mediator 
(e.g. hexacyanoferrate (III) ion) and it is then oxidized at the working electrode producing a 
measurable electric current, whose intensity under standardized conditions is proportional to the 
concentration of glucose.    
As an alternative, new emerging paper-based device platform can be used for developing 
portable analytical devices that are easy-to-use, cheap and fast. In particular, in order to obtain 
a sensitive and accurate analysis, it is possible to exploit a CL enzymatic reaction in which 
glucose is oxidised by GOx producing hydrogen peroxide. The hydrogen peroxide generated by 
this reaction, in presence of luminol and hexacyanoferrate (III), allows the production of photons 
which can be detected using portable instrumentation like CMOS device.  
Figure 3.5 Oxidation of β-D-glucose catalysed by the enzyme glucose oxidase, producing 
gluconolactone and hydrogen peroxide.  
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4. OBJECTIVES  
The present work is focused on the study of two different chemiluminescent bioanalytical 
assays.  
On one hand, a chemiluminescent immunoassay for detection of ATP is optimised. The aim 
of that study is three-fold: 
1. To choose the most suitable reagents and type of immunoassay in order to find the 
better conditions for the chemiluminescent competitive immunoassay.  
2. To optimise chemical conditions of the competitive immunoassay selected for 
obtaining suitable analytical performances.  
3. To make a calibration curve.     
On the other hand, the aims of the study about paper-based device with chemiluminescent 
detection for glucose quantification in serum samples are: 
1. To adapt a device tested before using a CCD camera to the use of a more compact 
and portable CMOS sensor for the detection.  
2. To make a calibration curve in the range of 50-250 µM of glucose in buffer solution of 
carbonate 0,1 M and another in human serum diluted 1:50 (V/V) to evaluate the matrix 
effect.  
3. To compare the calibration curves in carbonate 0,1 M buffer solution obtained using 
CMOS with those obtained in a previous study using CCD. 
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5. EXPERIMENTAL SECTION 
5.1. DEVELOPMENT OF CHEMILUMINESCENT IMMUNOASSAY FOR DETECTION OF ATP 
5.1.1. Reagents 
Non-fat dried milk bovine (Sigma Aldrich Chemical)  
Streptavidin (Thermo Fisher Scientific, 10 mg/mL) 
Bovine Serum Albumin (BSA) (Sigma Aldrich Chemical) 
Boric acid (Carlo Erba Reagents) 
Sodium carbonate (Carlo Erba Reagents) 
Sodium chloride (Carlo Erba Reagents) 
Sodium dihydrogen phosphate monohydrate (Carlo Erba Reagents) 
Disodium phosphate anhydrous (Carlo Erba Reagents) 
Phosphate Buffered Saline (PBS) 
Adenosine triphosphate (ATP) (Sigma Aldrich Chemical) 
HRP conjugated to biotin (HRP-Biotin) (Invitrogen) 
ATP conjugated to biotin (ATP-Biotin) (Enzo Life Sciences) 
ATP conjugated to Ovalbumin (ATP-OVA) (Cloud-Clone Corp, 0,1 mg/mL) 
ATP conjugated to BSA (ATP-BSA) (Cloud-Clone Corp, 0,1 mg/mL) 
Antibody Anti-ATP in rabbit (Abcam) 
Antibody Anti-ATP in rabbit (Cloud-Clone Corp) 
Antibody AntiRabbit conjugated to HRP (AntiRabbit-HRP) (Sigma Aldrich Chemical) 
Antibody Anti-Ovalbumin in mouse (Sigma Aldrich Chemical) 
Antibody Anti-Ovalbumin in rabbit (Sigma Aldrich Chemical) 
Antibody AntiMouse conjugated to HRP (AntiMouse-HRP) (Sigma Aldrich Chemical)  
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Chemiluminescent substrate for HRP (Supersignal ELISA Femto) (Thermo Fisher Scientific) 
5.1.2. Instruments 
Analytical balance (Sartorius) 
pH Meter (Beckman Coulter) 
Nitrocellulose (GE Whatman) 
96-well microplate (Thermo Fisher Scientific) 
Camera (MagZero 2 PRO, MagZero, Pordenone) based on CCD sensor (Sony ICX285 
(1360 x 1024 pixel)) 
Luminoskan Ascent Microplate Luminometer (Thermo Fisher Scientific) 
5.1.3. Selection of the reagents and optimization of the experimental conditions: 
nitrocellulose-based chemiluminescent immunoassay 
Optimization of the experimental conditions of the immunoreactions were performed by 
preliminary measurements using nitrocellulose membranes as platform allowing an easy and 
reproducible analysis. Competitive IA was selected as the most suitable format since ATP is a 
small molecule which is not indicated for a non-competitive (“sandwich”) method. Different 
reagents and different type of IA were tested to find the better conditions for the CL competitive 
IA. Being a competitive IA, these preliminary tests were performed in absence of ATP in the 
samples in order to select the reagents able to achieve the maximum signal (signal decreases 
at the increase of analyte concentrations) and to evaluate the performance of the 
immunoreagents. Three different type of IA were investigated: 
1. Indirect competitive immunoassay (a):  
This approach, shown in Figure 5.1, is based on the competition between ATP-Biotin and 
ATP present in the sample for binding the Anti-ATP antibody. Detection is performed by adding 
an anti-species antibody conjugated to HRP. This procedure required the preliminary 
immobilization of streptavidin on nitrocellulose membrane. Streptavidin has the task of binding 
ATP-Biotin which is too small molecule for being immobilized directly on nitrocellulose or plastic 
support. In this format two different antibodies were tested: one from Abcam and the other from 
Cloud-Clone Corp. 
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Streptavidin was immobilized on nitrocellulose membrane at the previously chosen 
concentration in borate buffer 0.05 M at pH 5. The immobilization was performed by spotting 
1µL of different solutions on nitrocellulose membrane. After the spot was dried, membranes 
were saturated by incubating them for 1 h in a solution of non-fat-dried milk 5% (V/V) diluted in 
PBS. Membranes were then washed three times using PBS (washing step). Then membranes 
were incubated for 1 h in a solution containing ATP-Biotin diluted 1:1000 in PBS (V/V). After 
washing step, membranes were treated for 1 h with a solution containing Anti-ATP antibody 
produced in rabbit diluted 1:500 in PBS (V/V). After another washing step membranes were 
incubated with AntiRabbit-HRP diluted 1:1000 in PBS (V/V) for 1 h. Finally, strip were washed 
once again and then CL signals were acquired by adding CL substrate and using CCD camera 
with integration time of 5 s.   
2. Indirect competitive immunoassay (b): 
This approach, shown in Figure 5.2, consists on the immobilization of ATP-OVA or ATP-
BSA on nitrocellulose membrane. ATP present in the sample and immobilized ATP-OVA or 
ATP-BSA compete for binding Anti-ATP antibody. Detection is performed by adding an anti-
species antibody conjugated to HRP.  
 
Figure 5.1 Indirect competitive immunoassay (a). 
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The procedure was performed using two different antibodies Anti-ATP (one purchased from 
Abcam and the other from Cloud-Clone Corp) in order to choose the one that gives suitable 
analytical performance. ATP-OVA was immobilized on nitrocellulose membrane at different 
dilutions (1:10, 1:100, 1:1000 (V/V)) in PBS buffer. The immobilization was performed by 
spotting 1 µL of different solutions on nitrocellulose membrane. After the spot was dried, 
membranes were saturated by incubating them for 1 h in a solution of non-fat-dried milk 5% 
(V/V) diluted in PBS. Membranes were subjected to a washing step. Then membranes were 
incubated for 1 h in a solution containing Anti-ATP produced in rabbit at different dilutions 
(1:1000, 1:10000, 1:100000 (V/V)) in PBS.  After washing step membranes were incubated for 1 
h with AntiRabbit-HRP diluted 1:1000 (V/V) in PBS. Finally, strip were washed once again and 
then CL signals were acquired by adding CL substrate and using CCD camera with integration 
time of 5 s.   
The Anti-ATP antibody selected was used to do the same procedure immobilizing ATP-
BSA.  
3. Direct competitive immunoassay: 
This approach, shown in Figure 5.3, consists on the immobilization of Anti-ATP produced in 
rabbit on nitrocellulose membrane. The ATP present in the sample and ATP-OVA compete for 
Figure 5.2 Indirect competitive immunoassay (b).  
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binding the immobilized antibody. Detection is performed by adding in sequence Anti-Ovalbumin 
produced in mouse and AntiMouse-HRP. 
 
 
 
 
 
 
 
 
 
Antibody Anti-ATP (purchased from Abcam) was immobilized on nitrocellulose membrane at 
different dilutions (1:100, 1:1000, 1:10000 (V/V)) in PBS. The immobilization was performed by 
spotting 1 µL of different solutions on nitrocellulose membrane. After the spot was dried, 
membranes were saturated by incubating them for 1 h in a solution of non-fat-dried milk 5% 
(V/V) diluted in PBS. Membranes were subjected to a washing step. Then membranes were 
incubated for 1 h in a solution containing ATP-OVA diluted 1:500 (V/V) in PBS.  After washing 
step membranes were incubated with Anti-Ovalbumin antibody produced in mouse diluted 1:500 
(V/V) in PBS. Then membranes were washed and incubated for 1 h with AntiMouse-HRP 
diluted 1:1000 (V/V) in PBS. Finally, strip were washed once again and then CL signals were 
acquired by adding CL substrate and using CCD camera with integration time of 5 s.   
 
For each experiment, a control strip was made to check if the immobilization had been 
correctly done. After the immobilization and saturation step, the control membrane was treated 
as follow: 
1. Immobilization of streptavidin: the membrane was treated for 1 h with HRP-Biotin 
diluted 1:500 (V/V) in PBS. After washing step, CL signals were acquired by 
adding CL substrate and using CCD camera with integration time of 5 s.   
Figure 5.3 Direct competitive immunoassay. 
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2. Immobilization of Ovalbumin-ATP: the membrane was treated for 1 h with Anti-
Ovalbumin in rabbit diluted 1:500 (V/V) in PBS. Then membranes were washed 
and incubated for 1 h with AntiRabbit-HRP diluted 1:1000 (V/V) in PBS. After 
washing step, CL signals were acquired by adding CL substrate and using CCD 
camera with integration time of 5 s.   
3. Immobilization of Anti-ATP produced in rabbit: the membrane was treated for 1 h 
with AntiRabbit conjugated to HRP diluted 1:1000 (V/V) in PBS. After washing 
step, CL signals were acquired by adding CL substrate and using CCD camera 
with integration time of 5 s.   
5.1.4. Experimental procedure of CL-based indirect competitive immunoassay in 
microplate format 
An assay was made to ensure the immobilization of ATP-OVA and the formation of the 
competitive IA selected on the microplate format. Thus, as in nitrocellulose assays, this first 
assay was made without the target analyte.  
A solution of ATP-OVA 10-4 mg/mL in carbonate buffer (pH 10, 0.05M) was used for coating 
96-well microplate with 100 µL per well and incubated overnight at 4°C. Wells were washed 
three times using for each well 300 µL of PBS (pH 8, 0.2 M) containing 3% BSA (w/V). The 
wells were saturated with the same solute ion for 4 h at 4°C. In order to verify the correct 
immobilization of ATP-OVA, wells were incubated for 1 h at room temperature with different 
dilutions of Anti-ATP (1:100, 1:1000, 1:10000 (V/V)) in PBS (100 µL per well). Control wells 
were incubated with Anti-Ovalbumin at the same dilutions and conditions. Once performed a 
washing step, wells were treated for 1 h at room temperature with AntiRabbit-HRP diluted 
1:2000 (V/V) in PBS (100 L per well). Finally, after a washing step, 100 µL of CL substrate 
was added and the CL signals were acquired using a luminograph with integration time of 200 
ms.  
Once the immobilization was confirmed, parameters as incubation time and the 
concentration of the Anti-ATP antibody were studied to define the procedure to make a 
calibration curve of the analyte. For that assays, solutions of ATP at different concentrations 
were used.  
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5.1.5. Data elaboration 
To obtain quantitative information, the mean photon emission intensity was measured and 
subtracted from background signal. Background signal was recorded using a well in which, after 
immobilization of ATP-OVA and saturation steps, was performed only the last step with 
incubation of AntiRabbit-HRP. Then to generate the calibration curve, it was calculated the ratio 
B/B0 in which B is the signal obtained for each analyte concentration while B0 is the maximum 
signal obtained in the absence of target analyte.  
As in every competitive method, the B0 value corresponds to the maximum binding of the 
tracer to the solid phase, while B is the signal for a specific concentration of the analyte where 
only a fraction of the tracer is bound to the solid phase. Therefore, the B/B0 ratio represent the 
fraction of the tracer that has been displaced by a specific concentration of the analyte and is 
included between 0 and 1. Values of B/B0 were then plotted against the log of analyte 
concentration obtaining a sigmoidal curve that is described by a four-parameter logistic function. 
5.2. PAPER-BASED DEVICE WITH CHEMILUMINESCENT DETECTION USING CMOS FOR 
THE DETERMINATION OF GLUCOSE 
5.2.1. Reagents 
Glucose oxidase from Aspergillus niger (Sigma Aldrich Chemical, 210 U/mg) 
Glucose (Sigma Aldrich Chemical) 
Hexacyanoferrate (III) of potassium (Sigma Aldrich Chemical) 
Luminol (5-Amino-2,3-dihydrophthalazine-1,4-dione, as a sodium salt) (Sigma Aldrich 
Chemical)  
Hydrogen peroxide (VWR Chemicals, 30%) 
Sodium carbonate (Carlo Erba Reagents) 
Phosphate Buffered Saline (PBS) 
Human serum 
5.2.2. Instruments 
Analytical balance (Sartorius) 
Chemiluminescent bioanalytical assays for clinical biomarkers.  27 
 
 
pH Meter (Beckman Coulter) 
Heating plate Arex (Velp Scientifica) 
Replicator 2X Experimental 3D Printer (MakerBot)  
Chromatographic paper (Whatman CHR, 20 x 20 cm) (Sigma Aldrich) 
Camera (MagZero 2 PRO, MagZero) based on CCD sensor (Sony ICX285 (1360 x 1024 
pixel)) 
CMOS sensor (Micron® Imaging MT9M001, Micron Technologies) 
5.2.3. From CCD to CMOS 
The analytical device was developed at first to be used in combination with a CCD camera. 
In this configuration, the darkroom was connected to the emission detection system which 
consisted of a camera based on a commercially available CCD sensor. The camera was 
equipped with a dual-cell Peltier thermoelectric cooling system that allowed to reduce sensor 
temperature to 40 ° C below room temperature. The possibility for the CCD sensor to operate at 
low temperatures is fundamental for reducing thermal background noise and for achieving the 
detection even of weak CL signals. Moreover the camera was used in ”contact imaging” 
configuration: the paper support was placed directly in contact with the CCD sensor through a 
fiber optic faceplate. The faceplate directly transfer CL signals to the CCD sensor allowing to 
obtain a more compact device and to increase the sensitivity by increasing the efficiency of 
collected light. The fiber optic element also acted as a thermal insulation, allowing the CCD 
sensor to cool down without affecting the temperature of the analytical module in which the CL 
reactions occur. 
Using this detector, the experimental parameters were optimized and the assay showed 
good analytical performances. However, although the device was compact and portable, 
reduction of power consumption, greater compactness and low-cost are required to obtain a 
LOC system.  
In this study, this assay was implemented in a fully-integrated system using a 
monochromatic CMOS sensor for the detection of CL signals (pixel size: 5.2µm x 5.2µm). 
CMOS sensor have a 1/2-inch CMOS active-pixel digital image sensor. It incorporates 
sophisticated camera functions and it is programmable through a simple two-wire serial 
interface. This megapixel CMOS image sensor is characterized by low-noise CMOS imaging 
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technology that achieves CCD image quality (based on signal-to-noise ratio and low-light 
sensitivity) while maintaining the inherent size, cost, low power consumption and integration 
advantages of CMOS.  
5.2.4. Origami device 
Origami, the art and science of paper, is a folding technique in which 3D objects are built 
from a planar paper. Recently this technique has been exploited to develop 3D paper-based 
microfluidic devices.   
The design of the origami paper-based device used in this study, shown in Figure 5.4, was 
made by using PowerPoint. Through the 3D printer and solid wax ink, the design was printed on 
chromatographic paper. Then, the printed paper was heated for a few minutes at approximately 
120 °C in a heating plate. With warming, the wax melts and penetrates into the paper pores 
generating the hydrophobic areas, which delimit the circular hydrophilic areas (active areas of 
the device that will contain the reagents) and the separation lines that make the device 
bendable (they become more flexible than the printed areas).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.4 Design of the hydrophobic areas of the origami device. In red, a single device.  
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In order to finish the preparation, the devices were cut individually and the reagents were 
added in every single device. After the addition of reagents in the proper circular area, the 
devices were left to dry protected from light. The function and the reagents contained in the 
various hydrophilic areas are described in Table 5.1, while Figure 5.5 shows the development of 
the device. 
Level Function and reagents 
1 – Hydrophilic area, Ø = 8 mm2  
Allows the uniform distribution of the buffer solution 
injected used as eluent. The bigger area guarantees a 
more homogeneous migration of the eluent on that 
level.  
2 – Hydrophilic area,  Ø = 6 mm2 
Contains 5 µL of GOx 1 U in buffer solution of PBS 
0,01 M (pH = 7,5). It is also the level where 10 µL of 
the sample, diluted 1:50 (V/V), containing glucose will 
be added.  
3 – Hydrophilic area,  Ø = 6 mm2 
Avoid the contact between the levels 2 and 4 when the 
device is folded 
4 – Hydrophilic area,  Ø = 6 mm2 
Contains 10 µL of hexacyanoferrate (III) of potassium 
0,02 M in buffer solution of carbonate 0,1 M (pH = 
10,0) 
5 – Hydrophilic area,  Ø = 8 mm2 
Contains 10 µL of luminol 0,2 M in buffer solution of 
carbonate 0,1 M (pH = 10,0). The bigger area allows 
this level to absorb a higher volume of eluent than the 
others favouring the elution of the reagents to that 
level  
6 – Transparent sticky tape 
Protect the camera from the eluent that has gone 
through all the levels 
  Table 5.1 Function and reagents content in each hydrophilic area of the origami’s device. 
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5.2.5. Adapters for origami-detection 
An important tool that ensures keeping the device in folded position during the 
measurement and that provides a slight pressure to get close contact between the various 
levels of the device is the holder (Figure 5.6). The holder presents three openings: the origami 
device can be inserted through its side opening, whereas the upper and lower allow the 
insertion of the eluent to the first level and the measurement of the CL signal from the last one, 
respectively.  
 
 
 
 
 
 
 
 
The connection between the holder and the CMOS camera is made by a dark chamber. 
This chamber does not allow the entrance of light into the system allowing the CL measure, 
guarantees the reproducible positioning of the holder over the faceplate of the CMOS and it also 
incorporates a hole through which a syringe can introduce the eluent in the first level of the 
Figure 5.5 Steps on origami’s device development from left to right: computer design, printed device, 
device after the thermic treatment and the addition of the reagents, and folded final configuration.     
Figure 5.6 Holder with and without the origami device inside. 
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origami device. Origami device was placed at a distance of 2.5 cm from CMOS sensor in order 
to focus the CL emission area. The whole instrumentation is shown in Figure 5.7. 
 
 
 
 
 
 
 
 
 
Both instruments were made of acrylonitrile-butadiene-styrene copolymer by using a 
commercial 3D printer.  
5.2.6. Experimental procedure 
The assay starts with the addition of 10 µL of the sample to the level 2 of the device. After 
10 minutes (which is the time required for the enzymatic reaction between glucose and the 
enzyme GOx for producing hydrogen peroxide) CL measurement is performed.  
For the measurement, the folded origami device is introduced in the holder and into the dark 
chamber as explained in paragraph 5.2.5. When 100 µL of the eluent are added by using the 
syringe, the hydrogen peroxide produced in level 2 and the solution of hexacyanoferrate (III) of 
potassium present in level 4 move to level 5 where the presence of luminol allows the CL 
reaction.  
A preliminary test was performed in order to compare the signal-to-noise ratio obtained 
using a CCD and a CMOS camera, respectively, and to ensure the reliability of the results 
obtained using the CMOS camera. Thus, instead of GOx and glucose, 10 µL of 100 µM 
hydrogen peroxide were added to the level 2 of the device.   
On the other hand, calibration curves were generated using glucose standard solutions in 
the range between 50 µM and 250 µM. Calibration curve was constructed by adding known 
amounts of glucose standard solutions to human serum diluted 1:50 (V/V). This was compared 
Figure 5.7 From left to right: CMOS camera in the device structure, opened device with the holder 
inside and device ready for the assay.  
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with a calibration curve obtained in carbonate buffer solution 0,1 M (pH = 10,0) to evaluate the 
matrix effect.  
5.2.7. Data elaboration 
The CL signal produced when the elution buffer on level 1 migrates through the underlying 
layers has a transient character (starts when the reagents come into contact and then declines 
slowly due to substrate consumption). 
It is known that for flash kinetic CL signals the total emission measurement results in better 
quantitative results than the evaluation of its maximum intensity. In principle, total emission 
could be measured by acquiring a single image with a sufficiently long exposure time but in 
practice it is not possible because the high number of photons collected would lead to saturation 
of the CMOS sensor with signal loss. This eventuality is avoided by acquiring a sequence of 
images with relatively short exposure times.  
Hence, sequence of images were acquired with a time exposure of 1 second and were 
analysed by using an ImageJ software v.1.46 (National Institute of Health, Bethesda, MD). This 
software allows the quantification of the CL signal of each image, thus, it was possible to 
represent the variation of the CL signal over the time. The mean photon emission intensity was 
measured in the areas corresponding to the area of interest. Each was subtracted from the 
mean background signal measured in the adjacent areas. The obtained values were integrated 
in order to obtain the total CL intensity emission. Calibration curves were obtained by plotting 
CL intensity values corresponding to different concentration of glucose against the glucose 
concentration and fitting the experimental data with a linear two-parameter logistic function. 
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6. DEVELOPMENT OF CHEMILUMINESCENT 
IMMUNOASSAY FOR DETECTION OF ATP: 
DISCUSSION  
6.1. OPTIMIZATION OF THE METHOD ON NITROCELLULOSE PLATFORM 
The results obtained for the three different competitive type of IA tested on nitrocellulose 
support in absence of the target analyte are described in the next paragraphs.  
6.1.1. Indirect competitive immunoassay (a) 
First, conditions for immobilizing streptavidin were evaluated. Thus, control strips were 
prepared by immobilizing different concentrations of streptavidin (from 10 mg/mL to 0,1 mg/mL) 
and dilutions were performed in borate buffer 0.05 M at pH 5. After making the complete 
procedure for the control strip described on the experimental part, the results obtained were 
those shown in Figure 6.1. The CL signal was obtained only at concentrations 10 and 1 mg/mL. 
The concentration of 10 mg/mL was chosen as the most appropriate from which to work. 
 
 
 
 
 
 
 
 
 
Once selected the concentration of streptavidin of 10 mg/mL, it was tested the 
immunological method, by treating a nitrocellulose membrane as described in paragraph 5.1.3. 
Independently of the Anti-ATP antibody used, the tested method gave no results, which means 
Figure 6.1 CL images of different concentrations of streptavidin spotted on nitrocellulose. 
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that competitive IA structure was not formed. In contrast, control membrane present a sharp and 
intense CL signal, confirming the correct immobilization of streptavidin.  
6.1.2. Indirect competitive immunoassay (b) 
The second indirect competitive IA was tested. First, in order to select the most adequate 
Anti-ATP antibody and after the use of each one in this format, the CL signal obtained was 
compared. As shown in Figure 6.2, while membrane treated with Anti-ATP from Abcam did not 
show any CL signal, the membrane treated with Anti-ATP from Cloud-Clone Corp. showed an 
intense CL signal in correspondence of the spot of ATP-OVA. Hence, Anti-ATP from Cloud-
Clone Corp was selected as the most suitable antibody to the test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Together with ATP-OVA, also ATP-BSA was immobilized and tested in the same conditions 
in order to select the best option for the performance of the assay. The Cloud-Clone Corp Anti-
ATP was used in this assay. Comparing the two options, showed in Figure 6.3, ATP-OVA was 
chosen since it allows to obtain better performance and higher CL signals. 
 
 
Figure 6.2 CL images of the membranes treated with two different antibodies. 
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In each assay, also the control strip was performed, obtaining CL signal and demonstrating 
that ATP-OVA and ATP-BSA were correctly immobilized.  
6.1.3. Direct competitive immunoassay 
As shown in Figure 6.4, Anti-ATP was correctly immobilized as evidenced by CL image of 
the control membrane where the spot corresponding to the maximum immobilized concentration 
of Anti-ATP showed a strong CL signal. On the contrary the membrane subjected to the 
complete protocol showed no CL signals. 
 
 
 
 
Figure 6.3 CL signals obtained after applying the complete protocol to different 
concentrations of ATP-OVA and ATP-BSA, respectively, using different concentrations 
of antibody.      
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6.2. OPTIMIZATION OF CHEMILUMINESCENT IMMUNOASSAY ON MICROPLATE FORMAT 
Accordingly to the obtained results, the indirect competitive immunoassay (b) was the 
selected approach. The Anti-ATP antibody chosen for the immunoassay was the one from 
Cloud-Clone Corp. The protocol was transferred to 96-microwell plate format.  
6.2.1. Immobilization of ATP-OVA 
The immobilization of ATP-OVA was studied as described in paragraph 5.1.4. Figure 6.5 
shows the results obtained for the competitive immunoassay applied. CL signals are 
proportional to antibodies concentrations, confirming the correct immobilization of ATP-OVA and 
the formation of the competitive IA structure.  
 
 
 
 
 
 
 
 
 
 
Figure 6.4 (a) CL images of the membrane subjected to the complete protocol; (b) control membrane. 
Figure 6.5 CL signal variation respect to Anti-ATP dilutions.  
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6.2.2. Incubation time 
In order to select the proper incubation time for the competitive step of the IA, two different 
approaches were tested. Following procedures were tested: 
a) Solutions of 100 µL containing different amount of ATP (from 20 to 0,3 nmol) and 
Anti-ATP diluted 1:1000 (V/V) in PBS were added into wells, where ATP-OVA had 
been previously immobilized and incubated for 1 h.  
b) Solutions of 100 µL containing different amount of ATP (from 20 to 0,3 nmol) and 
Anti-ATP diluted 1:1000 (V/V) in PBS incubated for 1 h out of wells. Then these 
solutions were transferred into wells, where ATP-OVA had been previously 
immobilized, and incubated for 1 h.  
The last incubation, common for both procedures, was made in a dilution of AntiRabbit-HRP 
1:1000 (V/V). 
As showed by Figure 6.6 while option (a) did not allow to discriminate between different 
concentrations of ATP, the option (b) allowed to obtain slightly changes of CL signals as the 
concentrations change. Probably this difference is due to the fact that Anti-ATP antibody has a 
higher compatibility with the ATP-OVA respect to ATP molecule, so a preliminary incubation of 
ATP with Anti-ATP is required.  
 
 
 
 
 
 
 
 
 
 
 
-  Figure 6.6 Variation of CL signal with ATP amount changes respect to maximum signal at 0 nmol of ATP 
(maximum signal) using different protocol for incubation. 
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Then it was also tested a lower incubation time (30 min) of the pre-mixed solution into wells. 
In this case, as shown in Figure 6.7, the CL signals were lowered significantly compromising the 
sensibility of the assay. 
 
 
 
 
 
 
 
 
 
 
 
 
6.2.3. Dilution of Anti-ATP antibody 
An important parameter that has to be evaluated is the dilution of Anti-ATP antibody. In 
order to select the proper dilution, tests were performed using different amount of ATP (0, 2, 20, 
200 nmol) in presence of different dilution of Anti-ATP (1:1000, 1:5000, 1:10000 (V/V) in PBS). 
ATP-OVA 10-4 mg/mL had been previously immobilised and the last incubation was made in an 
AntiRabbit dilution 1:1000 (V/V). 
 Results are showed in Figure 6.8. The dilution that allowed to significantly distinguish 
between different concentrations of ATP is 1:5000. In fact, dilution 1:1000 allowed to 
discriminate the blank samples from other concentration but it was not possible to distinguish 
different concentration of ATP from each other. Dilution 1:10000 showed a significant change in 
CL signal between 2 and 20 nmol of ATP but there was no difference between 20 and 200 
nmol.  
 
Figure 6.7 Variation of CL signal with ATP amount changes using different time of incubation out wells. 
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6.3. CALIBRATION CURVE 
In the following lines, the procedure used to make the calibration curve of ATP is described. 
It is based on the results obtained in the previous section.  
A solution of ATP-OVA 10-4 mg/mL in carbonate buffer (pH 10, 0.05M) was used for coating 
96-well microplate with 100 µL per well and incubated overnight at 4°C. Wells were washed 
three times using for each well 300 µL of PBS (pH 8, 0.2 M) containing 3% BSA (w/V). The 
wells were saturated with the same solute ion for 4 h at 4°C. In the meanwhile, ATP standard 
solutions with different quantity of ATP (in the range of 0,0025 – 250 nmol) and Anti-ATP 
antibody produced in rabbit diluted 1:5000 in PBS (V/V), incubated for 1 h at room temperature. 
After washing microplates well as previously described, 100 µL of each solution of ATP and 
anti-ATP antibody produced in rabbit was transferred into wells and incubated for 1 h at room 
temperature. A washing step was performed and a solution containing Anti-Rabbit-HRP diluted 
1:1000 (V/V) in PBS was added into wells (100 µL per well) and incubated 1 h at room 
temperature. Finally, after a washing step, 100 µL of CL substrate was added and the CL 
signals were acquired using a luminograph with integration time of 200 ms. 
Calibration curve obtained is shown in Figure 6.9. Being a competitive type format, the 
decrease of the B/B0 ratio was directly proportional to the amount of the analyte in the sample. 
The results of repeated calibration curves demonstrated a good reproducibility with an average 
Figure 6.8 Selection of the proper dilution of Anti-ATP. 
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of the relative standard deviation associated with each point of the calibration curve of about 
10%. The limit of detection (LOD) was estimated as the number of moles corresponding to the 
blank value minus three times its standard deviation. The obtained value was 0,01 nmol and the 
dynamic range extend from 0,01 to 80 nmol. Results were expressed in nmol and not in 
concentration, as the nature of the sample is still unknown.  
 
 
 
 
 
 
 
 
 
Figure 6.9 Calibration curve. 
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7. PAPER-BASED DEVICE WITH CHEMILUMINESCENT 
DETECTION USING CMOS FOR THE DETERMINATION 
OF GLUCOSE: DISCUSSION 
7.1. CMOS SENSOR DETECTABILITY AND RESOLUTION 
Preliminary test was performed as described in section 5.2.6. A solution of hydrogen 
peroxide 100 µM was used in order to compare the signal-to-noise ratio obtained with the 
reference CCD camera and CMOS sensor. As reported in Figure 7.1, CCD showed a higher 
signal-to-noise ratio compared with that obtained using a CMOS sensor. This is due to the fact 
that CMOS detector is less sensitive than a CCD because the latter is cooled at 40 °C below 
room temperature and presents larger pixel size. The CL intensity profiles measured across the 
circle show that the peaks are resolved at the baseline, showing that resolution offered by the 
different detector was comparable.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Comparison of the signal-to-noise ratio of the CL signal, obtained in the middle of the kinetic 
profile using, using (a) CMOS sensor and (b) CCD camera.  
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7.2. CALIBRATION CURVE 
Calibration curve was generated adding glucose standard solutions in the range of 50 to 
250 µM in carbonate buffer solution. Figure 7.2 shows the kinetic profile of the CL signal 
obtained. The kinetics are coherent as the CL signal area is proportional to the concentration of 
glucose.  
 
 
 
 
 
 
 
 
 
 
 
 
Comparison between calibration curve obtained with CCD and with CMOS is reported in 
Figure 7.3. The calibration curve performed using CMOS, y = (2160 ± 80)x + (-18000 ± 12000), 
presented a better linear correlation, R2 > 0,99, than the one obtained using CCD, y = (7,0 x 107 
± 3 x 106)x + (2 x 108 ± 4 x 108), that has a linear correlation of R2 > 0,97. This is probably due 
to the fact that CMOS’ curve has one fewer point on it.  
The limit of detection (LOD) was estimated as the concentration corresponding to the blank 
value plus three times its standard deviation. The obtained value was then interpolated in the 
calibration curve. The obtained values were 30 µM using CMOS and 10 µM using a CCD while 
the dynamic ranges of the method extended from 30 to 250 µM and from 10 to 250 µM, 
respectively. Even if CCD camera allowed to obtain a lower LOD, nevertheless CMOS detector 
allowed to evaluate glucose concentration in both normal and pathological conditions. 
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Figure 7.2 Kinetic profile of CL signal obtained for the range of 50 – 250 µM of glucose. 
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7.3. APPLICATION ON REAL SAMPLES: CALIBRATION CURVE IN HUMAN SERUM 
In order to evaluate the applicability of the method to the analysis of real samples, 
calibration curve was generated by adding known concentration of glucose into human serum 
instead of carbonate buffer solution. This calibration curve was then compared to that obtained 
in buffer. 
Preliminarily, the optimum dilution factor for the sample was established based on the 
nominal blood glucose values, which are between 3,9 and 6,1 mM. Considering this range of 
values, it was decided to dilute samples 1:50 (V/V) so that a sample with a maximum nominal 
blood glucose coincides to the half of the calibration curve. This dilution would thus allow to 
discriminate both hypoglycaemic and hyperglycaemic specimens. 
The results obtained are shown in Figure 7.4. The equation obtained for the calibration 
curve in serum was y = (2420 ± 230)x + (339000 ± 35000) and the linear correlation was R2 > 
0,97. The slope obtained for both calibration curves were similar (2160 ± 80 in buffer versus 
2420 ± 230 in serum), as could be assumed, given that the high dilution of the sample should 
reduce the matrix effect. These preliminary results therefore suggest the applicability of the 
method for determining glucose content in serum (and presumably plasma) samples. Based on 
the results it is also concluded that the concentration of glucose of the used serum pool is just 
over 7.1 mM that is slightly over the physiological range. 
Figure 7.3 Calibration curves of glucose, in the range of 50 – 250 µM,  in carbonate 0,1 M buffer 
solution obtained using a CMOS sensor (on the left) and CCD camera (on the right). Each 
measurement is the average of three replicates.  
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Figure 7.4 Comparison between the calibration curve performed in carbonate 0,1 M buffer 
solution and the performed in serum 1:50 (V/V). Each measurement is the average of three 
replicates.  
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8. CONCLUSIONS 
As seen, the study was divided in two projects. The conclusion obtained for each one are:  
1. Optimization of an immunoassay for ATP detection.  
- The indirect competitive CL-based immunoassay, which consists in the competition 
between ATP present in the sample and immobilized ATP conjugated to ovalbumin for 
binding Anti-ATP antibody, was choosen as the most suitable immunological format after 
the assays in nitrocellulose.  
- The immunoassay format choosen was correctly transferred to microplate format. After the 
optimization it was decided that proper incubation time was 1 h out of wells and the Anti-
ATP antibody dilution chose was 1:5000.   
- The CL immunoassay showed good analytical performances achieving high detectability 
(LOD: 0.01 nmol).  
- The next step for this project will be the implementation of this immunoassay on a portable 
platform integrated with a-Si:H photosensors for the CL detection. The implementation of 
the CL bioassay into the compact and fully-integrated device will provide a new analytical 
platform for the multiparametric detection of bio-organic molecules outside of the Earth. 
2. Paper-based device with chemiluminescent detection for glucose quantification in 
serum samples 
- The adaptation of the device to the use of CMOS sensor for the detection was successfully 
achieved. 
-  CMOS sensor provides more compactness and portability than CCD camera without a 
significant loss in detectability. Moreover the use of CL as detection principle made it 
possible to achieve high sensitivity with a limit of detection of 30 µM of glucose. 
- In the future this device could be adapted for the detection of different biomarkers and for 
multiplexed analysis. The high sensitivity and the simplicity of the system pave the way for a 
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new generation of analytical devices that can be easily used for a wide range of in-field and 
point-of-care bio-analyses. 
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10. ACRONYMS 
POCT Point-of-care testing 
CL Chemiluminescence 
HRP Horseradish peroxidase 
PMT Photomultiplier tube 
CCD Charge-couple device 
CMOS Complementary metal oxide semiconductors 
IA Immunoassay 
LOC Lab-on-chip 
LMC Life marker chip 
PLEIADES Planetary Life Explorer with Integrated Analytical Detection and Embedded 
Sensors 
ATP Adenosine Triphosphate 
GOx Glucose oxidase 
BSA Bovine serum albumin 
PBS Phosphate Buffered Saline  
HRP-Biotin HRP conjugated to biotin  
ATP-Biotin ATP conjugated to biotin  
ATP-OVA ATP conjugated to Ovalbumin  
ATP-BSA ATP conjugated to BSA  
AntiRabbit-HRP Antibody AntiRabbit conjugated to HRP  
AntiMouse-HRP Antibody AntiMouse conjugated to HRP  
 
  
 
